Actively Recruiting
Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery
Led by Hôpital Privé de la Baie · Updated on 2026-04-01
46
Participants Needed
1
Research Sites
164 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glaucoma is an irreversible optic neuropathy. It is the second most common cause of blindness worldwide. Glaucoma can be treated with topical medications (eye drops), laser or surgery. Traditional surgery is invasive and has a high complication rate (hypotonia, endophthalmitis, cataracts, etc.). As a result, several types of micro-invasive surgery (MIGS) have been developed to reduce the risks of surgery while maintaining their effectiveness in lowering intraocular pressure (IOP). The ELIOS laser system is the only ophthalmological excimer laser designed for the surgical treatment of glaucoma. The aim of the procedure is to ablate the trabecular meshwork and inner wall of Schlemm´s canal ab interno, with the creation of 10 microchannels of 210 um in the trabeculum using the ELIOS laser with a wavelength of 308 nm, in order to improve trabecular outflow to achieve a reduction in IOP. The ELIOS laser is an example of Microinvasive Glaucoma surgery (MIGS) with published results demonstrating efficacy and safety. The ELIOS laser is already in use in France (AMM / CE mark achieved). Its use as part of a prospective interventional study will enable us to collect data in order to treat patients more effectively and improve the quality of care provided to glaucoma patients.
CONDITIONS
Official Title
Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older who agree to participate and have signed informed consent
- Visually significant cataract requiring surgery
- Diagnosis of primary open-angle glaucoma or secondary open-angle glaucoma (pseudoexfoliative or pigmentary) with indication for cataract surgery
- Open iridocorneal angle with Shaffer grade 2 to 4
- Early to moderate glaucoma (visual field mean deviation better than -12 dB)
You will not qualify if you...
- Severe systemic diseases
- Pregnant or breastfeeding women
- Under 18 years of age
- Other eye diseases besides cataracts, including severe dry eye
- History of intraocular surgery, eye trauma, or conjunctival scarring in the surgical area
- Visual acuity worse than counting fingers
- Closed iridocorneal angle or angle-closure glaucoma, neovascular glaucoma, or iris neovascularization
- Normal-pressure glaucoma
- Corneal thickness less than 490 µm or greater than 620 µm
- Visual field mean deviation worse than -12 dB
- Intraocular pressure above 35 mmHg
- Autoimmune diseases, especially collagen disorders
- Under protective supervision
- Not covered by social security
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Privé de la Baie
Avranches, France, 50300
Actively Recruiting
Research Team
A
Ana Miguel, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here